Hot Investor Mandate: China Cross-Border Firm Invests Up to $30M in Clinical Stage Therapeutics & Near Market Ready Devices and Diagnostic Companies

15 Aug

A cross-border life science investment firm focuses on the pharmaceutical, medical device, and diagnostics sectors. In addition to investment, the firm is actively involved in supporting their portfolio companies through cross-border partnerships. The firm generally makes investments ranging from $5-30 M, and is currently seeking global opportunities.

For pharmaceuticals, the firm looks at assets ranging from Ph I to marketed with a preference towards post-Phase IIb products, but is open to promising, earlier stage opportunities with strong clinical data. For medical device products, the firm looks at a wide variety of products with a preference for technologies that are soon to be market ready. Sector interests include but are not limited to cardiovascular, surgical, ENT, orthopedics, wound care, robotics, and others. For diagnostics, the firm invests in a broad range of technology including POCT, IVD, and molecular diagnostics but also targets non-conventional and invasive diagnostics (such as IVUS/OCT, breath based, GI, etc…). The firm is also interested in revenue generating companies working in the animal health space.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: